Since the enactment of the National Cancer Act in 1971, the U.S. has spent hundreds of billions of dollars in cancer research and treatment. And yet, the cancer mortality rate—the historic benchmark of progress—has only declined modestly while the mortality rates of other leading causes of death have declined substantially.
This difference has led many to question whether we've made progress in the 'War on Cancer'. The answer is definitively yes according to Norris Cotton Cancer Center research published Monday in the Journal of Clinical Oncology.
"Our findings show that we have made steady progress against the burden of many cancers for decades," said lead author Samir Soneji, PhD, assistant professor for Geisel School of Medicine at Dartmouth and the Dartmouth Institute for Health Policy and Clinical Practice. "We have underestimated the progress because, as fewer and fewer people die from heart disease, stroke, and accidents, more and more people are living longer and having more years in which to develop and die from cancer."
According to Soneji the accuracy of existing measurements for the nation's progress against the burden of cancer are limited because they reflect progress against other diseases. Soneji and his colleagues Hiram Beltrán-Sánchez, PhD, and Harold C. Sox, MD, measured the effect of cancer prevention, screening, and treatment on the burden of cancer mortality while taking account of the increased incidence of cancer because people are living longer as a result of progress against other leading causes of death.
To solve a problem first identified by the National Cancer Institute (NCI) 20 years ago, Dartmouth cancer researchers started with a measure of the burden of cancer mortality called the years of life lost due to cancer, which reflects how much longer we might expect to live if cancer did not exist. They then separated the favorable effect of advancements in cancer care from the unfavorable effect on cancer incidence due to advancements in the care of other diseases, notably cardiovascular disease.
"We estimate how the years of life lost from cancer are directly affected by cancer mortality and indirectly affected by increased cancer incidence because of greater longevity due to improvements in primary prevention, detection, and treatment of other disease," said Soneji. With this approach cancer control researchers at Norris Cotton Cancer Center were able to measure how much progress the U.S. has made against the burden of cancer mortality in America.
Soneji's research concluded that the decrease in lung cancer mortality rates between 1985 and 2005 tripled their contribution to reducing the years of life lost due to cancer. Yet not all of this progress was actually realized because other-cause mortality rates also decreased. The resulting increase in life expectancy and its consequent increase in lung cancer incidence partially offset this progress. "The decline in cigarette smoking, which began in the 1960s, is almost certainly the main reason the burden of lung cancer mortality declined," said Soneji.
Authors Soneji, Beltrán-Sánchez, and Sox also found consistent progress in reducing the burden of colorectal cancer mortality since 1985. More recent, but less consistent, progress has been made in reducing the burden on prostate and breast cancer deaths.
"Our approach reveals more accurately the aggregate contribution of cancer prevention, screening, and treatment on progress against cancer," said Soneji.
To date, survival time and mortality rates have been the leading population-level measures of cancer burden. These measures assess the effect of prevention, screening, and treatment on cancer, but they fail to account for changes in other-cause mortality rates. In contrast, Soneji and his colleagues used a more comprehensive measure that accounts for both changes in cancer mortality rates and changes in other-cause mortality rates. By accounting for progress against other leading causes of death, researchers can now more accurately assess progress against cancer. Whether historical progress in cancer continues in the future depends, in large part, on whether cigarette smoking continues to decline and effective screening detects earlier and more treatable stages of cancer.
This study was funded in part by NCI grant #RC2CA148259 and National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number KL2TR001088.
About Norris Cotton Cancer Center at Dartmouth-Hitchcock
Norris Cotton Cancer Center combines advanced cancer research at the Geisel School of Medicine at Dartmouth with patient-centered cancer care provided at Dartmouth-Hitchcock Medical Center, at Dartmouth-Hitchcock regional locations in Manchester, Nashua, and Keene, NH, and St. Johnsbury, VT, and at 12 partner hospitals throughout New Hampshire and Vermont. It is one of 41 centers nationwide to earn the National Cancer Institute's "Comprehensive Cancer Center" designation. Learn more about Norris Cotton Cancer Center research, programs, and clinical trials online at cancer.dartmouth.edu.
Donna Dubuc | EurekAlert!
The Great Unknown: Risk-Taking Behavior in Adolescents
19.01.2017 | Max-Planck-Institut für Bildungsforschung
A sudden drop in outdoor temperature increases the risk of respiratory infections
11.01.2017 | University of Gothenburg
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences